Science Friday
A Vaccine For Pancreatic Cancer Continues To Show Promise
Feb 26, 2025
Dr. Vinod Balachandran, an expert in pancreatic cancer treatment at Memorial Sloan Kettering, discusses groundbreaking advancements in vaccine development. He shares promising results from a small trial of an mRNA vaccine that showed half of the participants developed a lasting immune response. Remarkably, six out of eight of these patients remained cancer-free for over three years. Balachandran emphasizes the potential of personalized vaccines and the revolutionary shift these could bring to cancer treatment, especially for hard-to-treat cancers.
17:50
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The development of a personalized mRNA vaccine for pancreatic cancer shows promise, with some patients remaining cancer-free for over three years after treatment.
- Recent research indicates that the immune system can be trained to recognize pancreatic cancer cells, challenging previous assumptions about immunotherapy effectiveness in this area.
Deep dives
Advancements in Pancreatic Cancer Vaccination
A research team is developing a promising vaccine for pancreatic cancer, which is notoriously difficult to treat with a high mortality rate. In an early small-scale clinical trial, 16 patients were vaccinated, resulting in notable immune responses in half of the participants, who exhibited no cancer recurrence after 18 months. The recent follow-up study found that those who responded to the vaccine maintained a lack of recurrence approximately three years later, highlighting the potential efficacy of this treatment. This research offers hope for new therapeutic avenues in combating other difficult cancers by teaching the immune system to recognize and attack cancerous cells.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
